Publicaciones en las que colabora con Leonardo Lorente Ramos (11)

2019

  1. High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

    BMC neurology, Vol. 19, Núm. 1, pp. 167

  2. Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients

    Journal of Critical Care, Vol. 51, pp. 117-121

2015

  1. Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction

    BMC Neurology, Vol. 15, Núm. 1

2014

  1. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury

    PLoS ONE, Vol. 9, Núm. 4

  2. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

    PLoS ONE, Vol. 9, Núm. 4

  3. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients

    Thrombosis Research, Vol. 134, Núm. 1, pp. 182-186

2013

  1. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis

    Critical Care, Vol. 17, Núm. 3

2012

  1. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, Núm. 6, pp. 1477-1487

2011

  1. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

    Critical Care, Vol. 15, Núm. 2

2010

  1. Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis

    Critical Care

2009

  1. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

    Critical Care, Vol. 13, Núm. 5